CIK 0001826457
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Monte Rosa Therapeutics, Inc.
Sign in to watch- Ticker
- GLUE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 617-949-2643
- Business address
- 321 HARRISON AVENUE, SUITE 900, BOSTON, MA, 02118
- Former names
- Monte Rosa Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $137
- in 1 filing
Net −$137. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-07-16 | Warmuth Markus President & CEO | Sale | −9,500 | $23.18 | $220K | 585,038 |
| 2026-06-01 | Warmuth Markus President & CEO | Sale 10b5-1 | −4,998 | $19.41 | $97K | 595,006 |
| 2026-06-01 | Warmuth Markus President & CEO | Sale 10b5-1 | −468 | $19.73 | $9K | 594,538 |
| 2026-05-01 | Warmuth Markus President & CEO | Sale 10b5-1 | −5,467 | $18.92 | $103K | 600,004 |
| 2026-04-14 | Warmuth Markus President & CEO | Sale | −8,000 | $17.64 | $141K | 605,471 |
| 2026-03-02 | Warmuth Markus President & CEO | Sale 10b5-1 | −5,466 | $17.92 | $98K | 613,471 |
| 2026-01-07 | Warmuth Markus President & CEO | Sale 10b5-1 | −3,707 | $23.24 | $86K | 620,696 |
| 2026-01-07 | Warmuth Markus President & CEO | Sale 10b5-1 | −1,450 | $23.88 | $35K | 619,246 |
| 2026-01-07 | Warmuth Markus President & CEO | Sale 10b5-1 | −309 | $24.57 | $8K | 618,937 |
| 2026-01-05 | Warmuth Markus President & CEO | Sale | −10,135 | $15.17 | $154K | 624,403 |
| 2026-01-02 | Warmuth Markus President & CEO | Grant or award | +90,000 | 634,538 | ||
| 2026-01-02 | Warmuth Markus President & CEO | Grant or award · Stock Option (Right to Buy) | +406,000 | 406,000 | ||
| 2025-01-02 | Warmuth Markus President & CEO | Grant or award | +128,000 | 544,538 | ||
| 2025-01-02 | Warmuth Markus President & CEO | Grant or award · Stock Option (Right to Buy) | +575,000 | 575,000 | ||
| 2024-01-02 | Warmuth Markus President & CEO | Grant or award · Stock Option (Right to Buy) | +346,000 | 346,000 | ||
| 2023-01-03 | Warmuth Markus President & CEO | Grant or award · Stock Option (Right to Buy) | +472,000 | 472,000 | ||
| 2022-03-01 | Warmuth Markus President & CEO | Grant or award · Stock Option (Right to Buy) | +315,600 | 315,600 | ||
| 2021-06-23 | Warmuth Markus See Remarks | Grant or award · Stock Option (Right to Buy) | +141,623 | 141,623 | ||
| 2021-04-12 | Warmuth Markus See Remarks | Grant or award · Stock Option (Right to Buy) | +538,517 | 538,517 |
Page 1 of 1 · 19 trades